source
- MoonLake reports all endpoints met in phase 3 trial of sonelokimab for psoriatic arthritisMoonLake Immunotherapeutics said its lead nanobody sonelokimab achieved positive topline results in a phase 3 study of patients with psoriatic arthritis. At week 16, 42.1% of participants reached…
- FDA approves Labcorp's BRAF melanoma companion diagnosticThe FDA has granted approval to Labcorp's companion diagnostic for advanced melanoma patients with specific BRAF mutations. The test, called PGDx elio tissue complete CDx, uses next-generation seq…